TY - JOUR
T1 - A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure
AU - O'Kane, Maurice
AU - Porter, David
AU - McCann, Michael
AU - Jülicher, Paul
AU - Christenson, Robert
AU - Oellerich, Michael
AU - Price, Christopher P.
AU - St John, Andrew
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - There is robust clinical trial evidence supporting the role of natriuretic peptides [NPs] in the assessment of patients presenting with suspected acute heart failure [AHF]. Despite the fact that clinical guidelines have for some time advocated NP measurement, the availability and uptake of NP testing in acute care services remains patchy and incomplete. The reasons for this are multifactorial but are underpinned by compartmentalised management and budget structures within complex healthcare delivery organisations. This paper outlines a value proposition for NP testing in the acute care setting which crosses the continuum of services and budgets. It articulates the expected benefits to each stakeholder in terms of efficiency of processes, clinical outcomes and cost effectiveness. It describes a pathway to implementation and suggests metrics that may be used to measure the effectiveness of introduction of NP testing. It is hoped that the value proposition will facilitate the uptake of NT testing fostering collaboration between laboratory, clinical, management and finance teams and by informing the development of business cases.
AB - There is robust clinical trial evidence supporting the role of natriuretic peptides [NPs] in the assessment of patients presenting with suspected acute heart failure [AHF]. Despite the fact that clinical guidelines have for some time advocated NP measurement, the availability and uptake of NP testing in acute care services remains patchy and incomplete. The reasons for this are multifactorial but are underpinned by compartmentalised management and budget structures within complex healthcare delivery organisations. This paper outlines a value proposition for NP testing in the acute care setting which crosses the continuum of services and budgets. It articulates the expected benefits to each stakeholder in terms of efficiency of processes, clinical outcomes and cost effectiveness. It describes a pathway to implementation and suggests metrics that may be used to measure the effectiveness of introduction of NP testing. It is hoped that the value proposition will facilitate the uptake of NT testing fostering collaboration between laboratory, clinical, management and finance teams and by informing the development of business cases.
UR - http://www.scopus.com/inward/record.url?scp=85075380599&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2019.09.023
DO - 10.1016/j.cca.2019.09.023
M3 - Article
C2 - 31655057
AN - SCOPUS:85075380599
SN - 0009-8981
VL - 500
SP - 98
EP - 103
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -